🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Aphria Pulls Out A Rare Cannabis Sector Win After Posting A Profit

Published 21/04/2020, 06:15 pm
GWPH
-
GTII
-
WEED
-
APHA
-
IIPR
-
CRON
-
TRUL
-
CURA
-

A Canadian-based marijuana company showed itself to be a bit of a unicorn last week, after posting a profit at a time when so many of its peers are hemorrhaging cash and struggling to survive through the deadly coronavirus pandemic.

Aphria (NYSE:APHA), (TSX:APHA) reported its third-quarter earnings after the closing bell on April 14 that included a net profit of C$5.7 million (US$4.025 million).

According to its financials, the cannabis grower saw its revenues for the three-month period that ended Feb. 29 reach C$144.4 million (US$101.95), almost double the C$73.6 million (US$51.96 million) in the same period in the previous year. Furthering the good news for investors was the fact the company showed it had just over C$515 million (US$363.59) in cash on its books.

However, Aphria opted to suspend its outlook for the rest of year due to the uncertainty caused by the COVID-19 health crisis.

Aphria Weekly Price Chart

The earnings report sent the company’s stock straight up, gaining almost 10%. It has since backtracked on those gains as it seesawed throughout most of the rest of last week. Aphria stock edged down more than 4% yesterday to close at US$3.44 (C$4.82).

Number of Billion-Dollar Cannabis Companies Dwindles

There has been a lot written about how pot stocks have been pummelled since the latter half of 2019. Investors have been battered and bruised as growers stumbled along the road to profitability. Many have yet to make it to that destination and continue to struggle.

As a measure of just how rough a road it has been for investors, consider this: at roughly this time last year, 17 cannabis companies of the more than 300 publicly traded companies in the sector on both sides of the Canada-U.S. border boasted market caps of US$1 billion (C$1.4 billion) or more. Today, there are only seven.

And although they still hover above the billion-dollar threshold, these companies have suffered significant losses in overall value. Here is a quick rundown of how they're faring:

  1. Canopy Growth (NYSE:CGC), (TSX:WEED) remains the biggest player in the field by market cap. This Ontario-based grower has a market cap of US$5.28 billion (C$7.49 billion). Although still the biggest, it has lost more than 64% of its value in the last year.

  2. GW Pharmaceuticals (NASDAQ:GWPH) is a UK-based company that is traded on the NASDAQ. It focuses on cannabinoid prescription medicines. It has a market cap of US$3.17 billion (C$4.5 billion). Its stock has lost about 32% in the last year.

  3. Cronos Group (NASDAQ:CRON), (TSX:CRON) is another Canadian based company traded both on the S&P/TSX Composite in Toronto and the NASDAQ. It has a market cap of US$2.07 billion (C$2.94 billion). It has lost just over 61% of its value in the last year.

  4. Massachusetts-based Curaleaf Holdings (OTC:CURLF), (CSE:CURA) has a market cap of US$1.88 billion (C2.67 billion), having lost more than 62% of its value in the last year.

  5. Green Thumb Industries (OTC:GTBIF), (CSE:GTII) is a Chicago-based national cannabis consumer retailer and packager with a market cap of US$1.21 billion (C$1.72 billion).

  6. Innovative Industrial Properties Inc (NYSE:IIPR) is a real estate investment trust for the medical cannabis industry and based in California. It has a market cap of US$1.25 billion (C$1.77 billion). Over the last year, its shares have lost just over 11% of their value.

  7. Trulieve Cannabis (OTC:TCNNF), (CSE:TRUL) is the largest medical marijuana company in Florida, with a market cap of US$1.03 billion (C$1.46 billion). In the last year its stock has lost about 35.5% of its value.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.